NewsCBDUK Regulators Confirm Key Testing Guideline For CBD Safety...

UK Regulators Confirm Key Testing Guideline For CBD Safety Studies


FOLLOWING days of uncertainty food regulators have today clarified their position on the path to compliance for CBD companies looking to continue to operate in the UK market next year.

On Monday, this week, the Association for the Cannabinoid Industry (ACI) said it had secured new guidance from the Food Standards Agency (FSA) on the toxicology testing data required to achieve Novel Food compliance.

This appeared to show a shift in the position of the FSA from the one it had outlined to the market in July, prompting much uncertainty for CBD businesses.

However, the FSA today updated its guidance, confirming that its position has not changed from the one previously outlined.

Monday’s ACI Claims

In July, UK regulators the FSA said in a public question and answer session with The Canna Consultants that Novel Food ‘Validations’ could be secured without toxicology tests having been undertaken.

However, earlier this week in press and social media statements and a pre-recorded video – which can be viewed here – the ACI summarised the FSA’s stance as follows.

-Novel foods applications will not be validated without the inclusion of toxicology safety data.

-This data does not exist and must be generated. Relying on data in the public domain is not sufficient.

FSA Outlines Its Position 

Today the FSA’s updated guidance outlines its position, saying:

An important part of any application will be a consideration of the product’s safety. 

Applicants will need to include details of the toxicological studies they have undertaken, or propose to undertake with clear details of the reasoning for these particular tests. 

Where all information isn’t available at the time of submission, a justification for the delay and when results will be available must also be included. Without such information it is unlikely we will be able to validate an application.

Toxicology Testing Is Required

In February, this year the FSA raised concerns about the safety of CBD and said it expected companies to comply with its Novel Food regulations by March 31, 2021.

It said it had concerns in relation to CBD’s potential impact on the liver and with certain groups such as mums-to-be and breast-feeding mums.

To secure a Novel Food Authorisation businesses must submit applications detailing the components of the CBD products and also demonstrate its safety for public consumption.

With CBD being such a relatively new phenomenon there is little available safety data and, it had become clear that this would have to be generated using in-vivo trials – most probably on rodents.

However, the FSA is still awaiting further guidance from its scientific advisors the Committee on Toxicity, therefore some businesses looking to undertake tests are still awaiting further guidance on what they need to test for.

With this not expected until near the end of the year many had been holding off, and in July, the FSA confirmed it would Validate Novel Food applications, as long as clear details of what the tests would examine were annotated in applications.

This has been confirmed today.

Novel Food – A Two-Stage Process

The Novel Food Authorisation process involves is a two-stage one, which sees an application initially Validated, which means it ticks all of the boxes required to move on to the next stage which is Authorisation.

The Authorisation stage can take up to nine months and sees the FSA examine all relevant data in relation to safety of the products to the consumer.

The Novel Food application and testing process is quite expensive with the ACI estimating it could cost between £300,000 to £1m.

The ACI had earlier announced plans to launch a study with a consortium of companies to demonstrate the safety of CBD.

Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

Latest news

Tilray’s Medical Cannabis Product Now Available And Reimbursed Under Ireland’s Medical Cannabis Access Program

PRESS RELEASE TILRAY Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis company inspiring and...

Grow Group, Kanabo, MGC Pharma & Celadon Pharma All Report Growing Revenues, But Continue To Post Losses

AMID the economic chaos that dominated the headlines over the past week, nearly half-a-dozen UK-based or UK-listed cannabis companies...

MGC Pharma Announces Appointment Of UK Advisor And New COO/Deputy CEO

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based bio-pharma company specialising in the production and development...

Sanity Group’s Record Funding Round Led By BAT Could Bring More Big-Tobacco Capital To Cannabis, But Concerns Remain Over Conflicts Of Interest

LAST week Berlin-based cannabis operator Sanity Group closed Europe’s largest ever cannabis investment round worth €37.6m, bringing its total...

European Cannabis Stocks Review: £22m Wiped From LSE-Listed Cannabis Stocks Amid Market Chaos

FOLLOWING a few weeks of relative positivity for many of the stocks listed on the London Stock Exchange (LSE),...

German SPD Representatives Confident A Solution To International Legal Hurdles Will Be Found

EARLIER this month news broke that recent analysis conducted by the Bundestag's scientific service suggested the creation of a...

Must read

You might also likeRELATED
Recommended to you